Clinical Study to Evaluate the Efficacy and Safety of Nab-Paclitaxel Combined With Cisplatin and Sintilimab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer

Inclusion Criteria: * Aged ≥ 18 years and ≤ 70 years; * Cervical cancer with pathological types being squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma; * Staged IB3 or IIA2 according to the FIGO 2018 staging system, as assessed by the investigator; * ECOG performance status of 0-2, or KPS score ≥ 70; * Expected survival time of more than 3 months; * Having at least one measurable lesion in accordance with RECIST 1.1; * Laboratory test results meeting the following criteria without drug intervention: 1. Hemoglobin ≥ 90 g/dl, neutrophil count ≥ 1.5 × 10⁹/L, platelet count ≥ 100 × 10⁹/L; 2. Creatinine ≤ 1.5 times the upper limit of normal range; 3. Total bilirubin, alanine transaminase (ALT), and aspartate transaminase (AST) \< 2 times the upper limit of normal; * Postmenopausal, or reproductive-aged women who meet all the following conditions: non-lactating, not pregnant, and able to use effective contraceptive measures during the study treatment period; * Voluntarily participating in this study and signing the informed consent form. Exclusion Criteria: * Participated in other clinical trials within 30 days before receiving the first dose of chemotherapy drugs or during the treatment period. * Previously received any other anti-tumor treatment for cervical cancer. * Non-HPV-related cervical cancer. * Needing to receive other anti-tumor treatments during the study treatment period. * Patients with known allergies to the active ingredients of the study drugs or their excipients. * Diagnosed with other malignant tumors in the past 5 years (except those judged to be cured by the investigator). * Active infections requiring systemic treatment. * Positive for human immunodeficiency virus (HIV) antibody. * Positive for hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) antibody. * Peripheral neuropathy with a grade of ≥ 2 according to the NCI-CTCAE (Version 5.0). * Concurrent diseases or abnormal test results that interfere with the subject's ability to receive anti-tumor treatment as judged by the investigator, such as the estimated inability of the subject to tolerate at least 2 cycles of neoadjuvant chemotherapy plus surgery or concurrent chemoradiotherapy, etc. Participation in this study is deemed not conducive to the maximum benefit of the subject as judged by the investigator.